Table 2 Correlation between clinicopathologic features, t(11;18)(q21;q21), and nuclear expression of BCL10 and NF-κB with tumor response to HP eradication therapy in HP-negative gastric MALT lymphomas.
Clinicopathologic characteristics | Tumors response to HPE regimen | P* | |
|---|---|---|---|
Antibiotic-responsive | Antibiotic-unresponsive | ||
(no. = 9) | (no. = 16) | ||
Age (median, range, years) | 61 (32–88) | 53.5 (20–76) | |
Sex, male/female | 6-Mar | 4-Dec | 0.087 |
Stage, no. (%) | 0.28 | ||
IE | 9 (100%) | 13 (81.2%) | |
IIE1 | 0 (0.0%) | 3 (18.8%) | |
Endoscopic features, no. (%) | 0.671 | ||
Ulceration, ulcerated mass, or giant nodular folds | 5 (55.6%) | 11 (68.8%) | |
Gastritis-like or erosions on infiltrative mucosa | 4 (44.4%) | 5 (31.2%) | |
Location of tumor(s), no. (%) | 0.1 | ||
Proximala or ≥2 components | 5 (55.6%) | 10 (62.5%) | |
Distalb | 4 (44.4%) | 6 (37.5%) | |
Depth of gastric wall involvement, no. (%)¶ | 0.345 | ||
Submucosa or above | 6/7 (85.7%) | 9/16 (56.2%) | |
Muscularis propria or beyond | 1/7 (14.3%) | 7/16 (43.8%) | |
API2-MALT1, no. (%) | 0.027 | ||
Negative | 9 (100%) | 9 (56.2%) | |
Positive | 0 (0.0%) | 7 (41.2%) | |
BCL10 expression, no. (%) | 0.001 | ||
Cytoplasmic or negative | 8 (88.9%) | 2 (12.5%) | |
Nuclear | 1 (11.1%) | 14 (87.5%) | |
NF-κB expression, no. (%) | 0.004 | ||
Cytoplasmic or negative | 8 (88.9%) | 4 (25.0%) | |
Nuclear | 1 (11.1%) | 12 (75.0%) | |
2nd-line treatment regimen | |||
Chlorambucil | 8 (50.0%) | ||
Rituximan-based | 3 (18.7%) | ||
Radiotherapy | 3 (18.7%) | ||
Observation | 2 (12.6%) | ||
